Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (7): 633-636.doi: 10.35541/cjd.20200431

• Reviews • Previous Articles     Next Articles

Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies

Shih Yanting1, Li Hao2, Zheng Jie1, Cao Hua1   

  1. 1Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Received:2020-05-06 Revised:2021-01-30 Online:2022-07-15 Published:2022-07-05
  • Contact: Cao Hua
  • Supported by:
    National Natural Science Foundation of China (81573037, 81872523); National Clinical Key Subject Construction Project(2012649); Shanghai Municipal Science and Technology Commission Medical Guide Project(134119a6100); Clinical Research Plan of Shanghai Shen-kang Hospital Development Center (16CR3084B); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20172009); Shanghai "Rising Stars of Medical Talent" Youth Development Program-Outstanding Youth Medical Talents (2019)

Abstract: 【Abstract】 After the specific binding of programmed death-1 (PD-1) to programmed death ligand 1(PD-L1), the PD-1/PD-L1 complex can exert a co-suppressive/co-stimulatory immunoregulatory effect, which can inhibit the activation and proliferation of T cells and their cytokine secretion, and play a key role in tumor immunity, autoimmunity and immune tolerance. This review summarizes structures and regulatory mechanisms of the PD-1/PD-L1 signaling pathway, aimming to facilitate the understanding of immune pathogenesis of idiopathic inflammatory myopathies complicated by malignant tumors, and to seek potential therapeutic targets and diagnostic strategies.

Key words: Programmed cell death 1 receptor, Myositis, Neoplasms, Immune checkpoint inhibitors, Anti-transcription intermediary factor 1-γ antibody